- Home
- ICCC vs AADI Comparison
ICCC vs AADI Comparison
Compare ICCC & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- AADI
- Stock Information
- Founded
- ICCC 1982
- AADI 2011
- Country
- ICCC United States
- AADI United States
- Employees
- ICCC N/A
- AADI 70
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- AADI Health Care
- Exchange
- ICCC Nasdaq
- AADI Nasdaq
- Market Cap
- ICCC 28.7M
- AADI 51.7M
- IPO Year
- ICCC 1987
- AADI N/A
- Fundamental
- Price
- ICCC $3.55
- AADI $2.10
- Analyst Decision
- ICCC
- AADI Hold
- Analyst Count
- ICCC 0
- AADI 3
- Target Price
- ICCC N/A
- AADI $1.75
- AVG Volume (30 Days)
- ICCC 20.8K
- AADI 102.0K
- Earning Date
- ICCC 11-13-2024
- AADI 11-06-2024
- Dividend Yield
- ICCC N/A
- AADI N/A
- EPS Growth
- ICCC N/A
- AADI N/A
- EPS
- ICCC N/A
- AADI N/A
- Revenue
- ICCC $23,222,929.00
- AADI $23,817,000.00
- Revenue This Year
- ICCC N/A
- AADI $4.79
- Revenue Next Year
- ICCC N/A
- AADI $10.72
- P/E Ratio
- ICCC N/A
- AADI N/A
- Revenue Growth
- ICCC 48.05
- AADI 10.57
- 52 Week Low
- ICCC $3.34
- AADI $1.21
- 52 Week High
- ICCC $5.59
- AADI $5.70
- Technical
- Relative Strength Index (RSI)
- ICCC 43.90
- AADI 63.80
- Support Level
- ICCC $3.51
- AADI $1.90
- Resistance Level
- ICCC $3.74
- AADI $2.17
- Average True Range (ATR)
- ICCC 0.17
- AADI 0.09
- MACD
- ICCC 0.00
- AADI 0.00
- Stochastic Oscillator
- ICCC 18.60
- AADI 70.49
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.